Septerna, Inc. (NASDAQ:SEPN - Get Free Report) shares gapped up prior to trading on Wednesday . The stock had previously closed at $14.54, but opened at $15.34. Septerna shares last traded at $14.57, with a volume of 10,601 shares trading hands.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on SEPN. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price target for the company. TD Cowen assumed coverage on Septerna in a research report on Tuesday, November 19th. They set a "buy" rating for the company. Cantor Fitzgerald assumed coverage on Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $50.00 price target on the stock. Finally, Wells Fargo & Company initiated coverage on Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price objective on the stock.
View Our Latest Analysis on Septerna
Septerna Stock Performance
The business's 50-day moving average price is $20.69.
Institutional Trading of Septerna
A number of large investors have recently modified their holdings of SEPN. New York State Common Retirement Fund purchased a new stake in shares of Septerna in the 4th quarter worth $32,000. PNC Financial Services Group Inc. bought a new stake in shares of Septerna in the fourth quarter valued at about $61,000. SG Americas Securities LLC bought a new stake in shares of Septerna in the fourth quarter valued at about $185,000. M&T Bank Corp purchased a new stake in Septerna in the fourth quarter worth about $376,000. Finally, Rhumbline Advisers bought a new position in Septerna during the 4th quarter worth about $458,000.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Further Reading
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
